Nonetheless, it can be concluded that low-dose IL2 therapy in conjunction with respective conservative therapy has proved to be a superior treatment modality for both SLE and RA, has limited adverse effects as compared to conventional therapy alone, and has a similar therapeutic application and safety profile in both autoimmune diseases. This evidence concerns the gene IL2 and systemic lupus erythematosus.